University of California San Francisco
Give to UCSF
Research led by scientists at the UCSF-affiliated Gladstone Institutes has identified the precise chain of molecular events in the human body that drives the death of most of the immune system’s CD4 T cells as an HIV infection leads to AIDS. Further, they have identified an existing anti-inflammatory drug that in laboratory tests blocks the death of these cells.
A new study provides further proof that regular use of the the HIV antiretroviral drug Truvada can reduce one’s risk for contracting HIV – without increasing sexual risk behavior.
UCSF is one of the first pharmacy schools in the nation to offer its students genetic testing for drug response. It’s just one way they're learning about the potential of precision medicine.
The protein in cells that most often drives the development of cancers has eluded scientists’ efforts to block it for three decades — until now.
UCSF scientists were able to arrest, and even reverse, tissue scarring of the liver, kidneys and lungs in mice. The scarring, also known as fibrosis, is a major factor in nearly half of all deaths in developed countries.
Through support from the Catalyst Awards, UCSF researcher Aditi Bhargava is working to develop a method for delivering small-molecules to a specific target group of cells for treatment of pain.
A UCSF opthamologist and bioengineer are collaborating to develop a tiny, flexible, implantable film that's able to deliver conventional medicines and also complex antibody-based drugs to treat eye diseases.
Often deadly “triple-negative” breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, UCSF reports.
Brian Alldredge, associate dean for the UCSF School of Pharmacy for the past 12 years and a member of the faculty for 28 years, has been named Vice Provost for Academic Affairs.
An antihistamine discovered in the 1950s to treat itching may also prevent seizures in an intractable form of childhood epilepsy, according to researchers at UC San Francisco who tested it in zebrafish bred to mimic the disease.
An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial, UCSF and Yale University report.
UCSF researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.
